Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513565 · ClinicalTrials.gov registry record · Phase 1
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00513565 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 22 participants.
The verdict
NCT00513565, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.
Interventions
- DRUG single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-09-13 |
| Est. Completion | 2009-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513565
The ClinicalTrials.gov registry entry for NCT00513565 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which single dose is the first listed.
NCT00513565 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513565 about?
NCT00513565 is a clinical study titled "A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers". This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.
What is the current status of trial NCT00513565?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-09-13. Estimated completion is 2009-05-14.
What interventions are being tested in trial NCT00513565?
The interventions under investigation include: single dose (DRUG).
Who is sponsoring clinical trial NCT00513565?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.